REGENXBIO, Inc. (RGNX)
10.43
+0.21
(+2.05%)
USD |
NASDAQ |
May 07, 16:00
10.46
+0.03
(+0.29%)
After-Hours: 06:25
REGENXBIO Research and Development Expense (Annual) : 212.68M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics, Inc. | 1.493B |
| Ocugen, Inc. | 37.36M |
| AbbVie, Inc. | 8.249B |
| Replimune Group, Inc. | 191.22M |
| Krystal Biotech, Inc. | 52.32M |